Liver resection for hepatocellular carcinoma in patients who have undergone prior renal transplantation

Cheng, Shao-Bin; Yeh, Dah-Cherng; Shu, Kuo‐Hsiung; Wu, Cheng‐Chung; Wen, Mei‐Chin; Liu, Tse‐Jia; P'eng, Facs Fang-Ku

doi:10.1002/jso.20465

Cited by 5 publications

(2 citation statements)

References 21 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Post‐surgical outcomes in ESKD patients undergoing gastrectomy and hepatectomy for gastric and hepatocellular cancer, respectively, are not different from the general population , 70,71 . Similar findings were seen for the kidney transplant patient requiring liver resection for cancer 72 . However, the incidence of massive ascites (35.3% vs 14.3%) and pleural effusion (52.9% vs 17.6%) is more common post operatively 71 .…”

Section: Surgery In Eskdsupporting

confidence: 54%

When ESKD complicates cancer screening and cancer treatment

Yasin

Holley

2020

Seminars in Dialysis

View full text Add to dashboard Cite

End-stage kidney disease (ESKD) affects the recommended screening, incidence, treatment, and mortality of cancer. Cancer occurring in a patient with ESKD can influence candidacy for kidney transplantation as well as dialysis decision-making and cancer treatment. Certain cancers are more common among ESKD patients, notably, viral-mediated cancers that are associated with human papilloma or hepatitis viruses, and urothelial cancers associated with analgesic and Balkan nephropathies. Solid tumors are not believed to occur more frequently in ESKD patients. The presence of ESKD may confer a higher risk of post-surgical complications as well as mortality. The cost-effectiveness of cancer screening depends upon individual cancer risk and estimated overall survival. The high mortality associated with ESKD argues against routine cancer screening in dialysis patients. Cancer treatment in ESKD may be complicated by the need to avoid, adjust doses of and/or coordinate the timing of administration of imaging contrast, chemotherapy, and immunotherapy with dialysis treatments. There is a general dearth of information on the treatment of cancer in ESKD patients. These issues will be discussed, and some general guidelines presented based upon the current literature.

show abstract

Section: Surgery In Eskdsupporting

confidence: 54%

When ESKD complicates cancer screening and cancer treatment

Yasin

Holley

2020

Seminars in Dialysis

View full text Add to dashboard Cite

show abstract

“…In light of these numerous risk factors, the primary focus of the present study was to characterize perioperative outcomes in patients with ESRD submitted to complex hepatopancreaticobiliary procedures. Most of the previous literature on this topic consists of relatively small single‐institution series, which have generally demonstrated the feasibility of performing safe hepatic or pancreatic resection in highly selected patients with renal dysfunction and ESRD . More recently, Squires and colleagues examined the effects of preoperative renal insufficiency on outcomes in a large series of patients undergoing pancreatic resection .…”

Section: Discussionmentioning

confidence: 99%